Last updated: November 26, 2024
Sponsor: Tanta University
Overall Status: Active - Recruiting
Phase
1/2
Condition
N/ATreatment
Labetalol Injection
HydrALAZINE Injection
Clinical Study ID
NCT06360601
36264PR589/3/24
Ages 25-45 Female
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- patient with clinical diagnosis of sever preeclampsia
Exclusion
Exclusion Criteria:
Patient with history of previous intracranial lesion Patient with history of heart disease/allergy to drug Patient with history of arrhythmia/anticoagulation Any craniotemporal lesion
Study Design
Total Participants: 40
Treatment Group(s): 2
Primary Treatment: Labetalol Injection
Phase: 1/2
Study Start date:
April 01, 2024
Estimated Completion Date:
December 20, 2024
Connect with a study center
Faculty of Medicine
Tanta, 3511
EgyptSite Not Available
Tanta Univeristy hospitals
Tanta,
EgyptActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.